- Home
- AGIO vs CCU Comparison
AGIO vs CCU Comparison
Compare AGIO & CCU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CCU
- Stock Information
- Founded
- AGIO 2007
- CCU 1850
- Country
- AGIO United States
- CCU Chile
- Employees
- AGIO N/A
- CCU N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CCU Beverages (Production/Distribution)
- Sector
- AGIO Health Care
- CCU Consumer Staples
- Exchange
- AGIO Nasdaq
- CCU Nasdaq
- Market Cap
- AGIO 2.1B
- CCU 2.2B
- IPO Year
- AGIO 2013
- CCU 1992
- Fundamental
- Price
- AGIO $36.39
- CCU $12.23
- Analyst Decision
- AGIO Buy
- CCU Strong Sell
- Analyst Count
- AGIO 6
- CCU 1
- Target Price
- AGIO $57.00
- CCU $10.00
- AVG Volume (30 Days)
- AGIO 771.2K
- CCU 149.5K
- Earning Date
- AGIO 10-30-2025
- CCU 11-05-2025
- Dividend Yield
- AGIO N/A
- CCU 2.52%
- EPS Growth
- AGIO N/A
- CCU 38.53
- EPS
- AGIO 11.13
- CCU 0.44
- Revenue
- AGIO $40,875,000.00
- CCU $3,254,866,554.00
- Revenue This Year
- AGIO $28.19
- CCU $10.29
- Revenue Next Year
- AGIO $152.14
- CCU $4.48
- P/E Ratio
- AGIO $3.27
- CCU $13.73
- Revenue Growth
- AGIO 30.57
- CCU 19.82
- 52 Week Low
- AGIO $23.42
- CCU $10.03
- 52 Week High
- AGIO $62.58
- CCU $15.75
- Technical
- Relative Strength Index (RSI)
- AGIO 51.16
- CCU 51.03
- Support Level
- AGIO N/A
- CCU $11.90
- Resistance Level
- AGIO $37.18
- CCU $12.47
- Average True Range (ATR)
- AGIO 1.43
- CCU 0.23
- MACD
- AGIO -1.50
- CCU -0.01
- Stochastic Oscillator
- AGIO 88.53
- CCU 63.01
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CCU Compania Cervecerias Unidas S.A.
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.